P2RY12 and coronary artery disorder: Recent studies have shown that a short course (1–3 months) of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy after percutaneous coronary intervention (PCI) have proven to be effective [5–7], highlighting the role of P2Y12 inhibitors in the management of CAD.